Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 2
1962 1
1964 1
1966 3
1967 2
1968 4
1969 2
1970 1
1971 1
1978 1
1979 1
1987 1
1988 1
1991 2
1992 1
1995 1
1996 1
1998 1
2001 1
2002 1
2003 2
2004 3
2006 2
2007 4
2008 1
2009 3
2010 2
2011 3
2012 1
2013 5
2014 4
2015 3
2016 1
2017 1
2020 2
2021 1
2022 1
2023 1
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Hepatic brucelloma.
Barutta L, Ferrigno D, Melchio R, Borretta V, Bracco C, Brignone C, Giraudo A, Serraino C, Baralis E, Grosso M, Fenoglio LM. Barutta L, et al. Among authors: brignone c. Lancet Infect Dis. 2013 Nov;13(11):987-93. doi: 10.1016/S1473-3099(13)70197-X. Lancet Infect Dis. 2013. PMID: 24156899 Review.
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial.
Wildiers H, Armstrong A, Cuypere E, Dalenc F, Dirix L, Chan S, Marme F, Schröder CP, Huober J, Duhoux FP, Vuylsteke P, Jager A, Brain E, Kuemmel S, Pápai Z, Menke-van der Houven van Oordt CW, Perjesi L, Mueller C, Brignone C, Triebel F. Wildiers H, et al. Among authors: brignone c. Clin Cancer Res. 2024 Feb 1;30(3):532-541. doi: 10.1158/1078-0432.CCR-23-1173. Clin Cancer Res. 2024. PMID: 37939105 Free PMC article. Clinical Trial.
A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology.
Al-Batran SE, Mueller DW, Rafiyan MR, Kiselicki D, Atmaca A, Habibzada T, Mueller C, Brignone C, Triebel F, Loose M, Schaaf M, Sookthai D, Eickhoff R, Jaeger E, Goetze TO. Al-Batran SE, et al. Among authors: brignone c. ESMO Open. 2023 Oct;8(5):101623. doi: 10.1016/j.esmoop.2023.101623. Epub 2023 Sep 22. ESMO Open. 2023. PMID: 37742484 Free PMC article. Clinical Trial.
Primary hepatic carcinoid: a case report and literature review.
Fenoglio LM, Severini S, Ferrigno D, Gollè G, Serraino C, Bracco C, Castagna E, Brignone C, Pomero F, Migliore E, David E, Salizzoni M. Fenoglio LM, et al. Among authors: brignone c. World J Gastroenterol. 2009 May 21;15(19):2418-22. doi: 10.3748/wjg.15.2418. World J Gastroenterol. 2009. PMID: 19452590 Free PMC article. Review.
Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma.
Forster M, Brana I, Pousa AL, Doger B, Roxburgh P, Bajaj P, Peguero J, Krebs M, Carcereny E, Patel G, Mueller C, Brignone C, Triebel F. Forster M, et al. Among authors: brignone c. Clin Cancer Res. 2024 Sep 3;30(17):3726-3734. doi: 10.1158/1078-0432.CCR-24-0473. Clin Cancer Res. 2024. PMID: 38995265 Clinical Trial.
Immunophenotyping of Peripheral Blood Mononuclear Cells in Septic Shock Patients With High-Dimensional Flow Cytometry Analysis Reveals Two Subgroups With Differential Responses to Immunostimulant Drugs.
Wang Y, Gloss B, Tang B, Dervish S, Santner-Nanan B, Whitehead C, Masters K, Skarratt K, Teoh S, Schibeci S, Fewings N, Brignone C, Triebel F, Booth D, McLean A, Nalos M. Wang Y, et al. Among authors: brignone c. Front Immunol. 2021 Mar 22;12:634127. doi: 10.3389/fimmu.2021.634127. eCollection 2021. Front Immunol. 2021. PMID: 33828550 Free PMC article.
68 results